Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

n asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit,
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... TOKIO , July 13, 2014 /PRNewswire/ ... Juli in Tokio ... der firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. ... umfassenden Überblick über die fortgeschrittenen klinischen Programme ... Das Ziel der Tagung bestand darin, aktuelle ...
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... July 26 Halt Medical, Inc. announced ... been appointed to its Scientific Advisory Board.  Dr. Rubin ... to develop and implement comprehensive reimbursement strategies.  Dr. Rubin,s ... of medicine, government, and business. Currently, he is Clinical ...
... Reportlinker.com announces that a new market research report is available in its ... 2008 U.S. Diabetes Drug Delivery - ... http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html , ... This study encompasses feedback provided by U.S. diabetes patients ...
Cached Medicine Technology:Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor 22008 U.S. Diabetes Drug Delivery - Patient Perspective 22008 U.S. Diabetes Drug Delivery - Patient Perspective 32008 U.S. Diabetes Drug Delivery - Patient Perspective 42008 U.S. Diabetes Drug Delivery - Patient Perspective 5
(Date:7/13/2014)... Genetics identifies a novel genetic and molecular ... (EoE), opening up potential new therapeutic strategies for ... EoE is a chronic inflammatory disorder of the ... to certain foods and an over-accumulation in the ... of the body,s immune system). EoE can cause ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... Vancouver, BC (PRWEB) July 13, 2014 ... creating excitement by promoting the rental of bikes for ... the historic downtown Victorian Hotel to tour the area ... day, plus tax. Bicycle enthusiasts love to call Vancouver ... many options for cycle travel and picturesque journeys through ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2
... the Y chromosome uses a neat trick to repair its ... from rotting away over evolutionary time. ,The Y chromosome, of ... makes males rather than females. ,Some scientists have suggested ... can't eliminate genetic defects in the usual way,// and broken ...
... Health Organisation said the world should be free of the ... but warned the disease could emerge in China again next ... within the next two-to-three weeks. SARS will be gone, we ... the only two areas still regarded as zones where the ...
... the onset of prostate cancer, however, finasteride may also ... men were randomized , age 55 or older to ... examination results were normal in all subjects, and prostate-specific ... Among the 4368 men in the finasteride group treated ...
... about something, let it out and it might save ... headaches internalize their anger more than those without headaches. ... study, 171 suffered from headaches. Investigators measured //trait anger ... hostility, anxiety and depression. Participants also provided information about ...
... vitamin D. ,Each year, 200,000 women in the United States ... form of the vitamin may enhance the effect of radiation ... with radiation alone to mice exposed to both radiation and ... tumor volume in those women treated //with EB 1089 was ...
... is most likely to be deadly when tumor cells spread ... a protein that may be able to predict a tumor’s ... ,Researchers from the University of Michigan Comprehensive Cancer Center are ... cancer cells to leave their original location and enter nearby ...
Cached Medicine News:Health News:Y chromosome uses trick to repair its own genes 2Health News:World SARS-free within weeks 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: